Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Sponsor: G1 Therapeutics, Inc.
A PHASE2 clinical study on Small Cell Lung Cancer, this trial is completed. The trial is conducted by G1 Therapeutics, Inc. and has accumulated 23 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Study Description(click to expand)The posted results represent the final results from Study G1T28-05, a Phase 2 study of carboplatin, etoposide, and atezolizumab with or without trilaciclib (G1T28) in patients with untreated extensive-stage small cell lung cancer (SCLC).
The final myelopreservation efficacy results are from database lock 1 (data cut-off \[DCO\] 17 Aug 2018). The final anti-tumor efficacy data (BOR, DOR, PFS) are from a second database lock 2 (DCO 28 June 2019) that occurred to support the trilaciclib New Drug Application (NDA). Final overall survival and safety data are reported from the final study database lock (DCO 11 Dec 2020, last patient last visit date of 29 October 2020).
Please note the last patient last visit date description above which is recorded as the study completion date. Following the last patient last visit, the final database lock occurred a few weeks later which accounts for the discrepancy between the study completion date and the reported assessment time frames.
The posted results represent the final results from Study G1T28-05, a Phase 2 study of carboplatin, etoposide, and atezolizumab with or without trilaciclib (G1T28) in patients with untreated extensive-stage small cell lung cancer (SCLC).
The final myelopreservation efficacy results are from database lock 1 (data cut-off \[DCO\] 17 Aug 2018). The final anti-tumor efficacy data (BOR, DOR, PFS) are from a second database lock 2 (DCO 28 June 2019) that occurred to support the trilaciclib New Drug Application (NDA). Final overall survival and safety data are reported from the final study database lock (DCO 11 Dec 2020, last patient last visit date of 29 October 2020).
Please note the last patient last visit date description above which is recorded as the study completion date. Following the last patient last visit, the final database lock occurred a few weeks later which accounts for the discrepancy between the study completion date and the reported assessment time frames.
Status Flow
Change History
23 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE2
-
Oct 2025 — Present [monthly]
Completed PHASE2
Status: Terminated → Completed
-
Sep 2025 — Oct 2025 [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
▶ Show 18 earlier versions
-
Jun 2022 — Jul 2024 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Apr 2022 — Jun 2022 [monthly]
Active Not Recruiting PHASE2
-
Feb 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Aug 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE2
-
Aug 2019 — Aug 2020 [monthly]
Active Not Recruiting PHASE2
-
Oct 2018 — Aug 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Nov 2017 — Mar 2018 [monthly]
Recruiting PHASE2
-
Oct 2017 — Nov 2017 [monthly]
Recruiting PHASE2
-
Sep 2017 — Oct 2017 [monthly]
Recruiting PHASE2
-
Aug 2017 — Sep 2017 [monthly]
Recruiting PHASE2
-
Jul 2017 — Aug 2017 [monthly]
Recruiting PHASE2
-
Jun 2017 — Jul 2017 [monthly]
Recruiting PHASE2
Status: Active Not Recruiting → Recruiting
-
May 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE2
Status: Not Yet Recruiting → Active Not Recruiting
-
Feb 2017 — May 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- G1 Therapeutics, Inc.
- Roche-Genentech
For direct contact, visit the study record on ClinicalTrials.gov .